Value of Wilms tumor gene product (WT-1) immunohistochemical expression in ovarian neoplasms

 
 
 
  • Abstract
  • Keywords
  • References
  • PDF
  • Abstract


    Background: Ovarian cancer is a fatal malignancy among females worldwide. The wide morphologic variation among ovarian neoplasms poses diagnostic difficulties. Wilms' tumor gene protein (WT-1) is a recently added marker to the diagnostic panel of ovarian neoplasms and may have prognostic implications.

    Objective: To evaluate the immunohistochemical expression of WT-1 protein in a broad array of ovarian neoplasms including metastases, identify its value in diagnosis and find out its association with the histopathological parameters including histological subtype, grade and FIGO stage.

    Materials and methods: This retrospective study was conducted on 93 ovarian neoplasms collected from Pathology Department, Mansoura University and Mansoura Oncology Center. Immunohistochemistry was performed for WT-1 protein using the avidin-biotin-peroxidase technique. Nuclear staining of tumor cells was considered as positive. Statistical analysis was performed using SPSS version 16.0.

    Results: Significant statistical difference in WT-1 expression was observed among histological types of ovarian neoplasms (p=0.04) being detected in 90% of serous tumors, in which significant statistical association was found between WT-1expression and grade (p=0.025), but not with stage. Most non-serous carcinomas were WT-1 negative. WT-1 reactivity was observed in tumors with Sertoli cell differentiation but undetectable in all other sex cord, germ cell, mixed germ cell-sex cord or metastatic tumors.

    Conclusions: WT-1 is a highly specific marker for ovarian serous carcinomas versus other histological subtypes of ovarian neoplasms including metastases. It should be included in the immunohistochemical workup of carcinoma of unknown primary in women or in a panel to verify Sertoli cell differentiation in sex cord-stromal tumors.

    Keywords: Immunohistochemistry, Ovarian Neoplasms, Serous Carcinoma, Sex-Cord, WT-1.


  • References


    1. Netinatsunthorn W, Hanprasertpong J, Dechsukhum C, Leetanaporn R, Geater A (2006) WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study. BMC Cancer 11(6), 90-95.
    2. Kritpracha K, Hanprasertpong J, Chandeying V, Dechsukhum C, Geater A (2005) Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 im-munostaining. J Obstet Gynaecol Res 31, 268-276.
    3. Bagby C, Ronnett BM, Yemelyanova A, Maleki Z, Kuhn E, Vang R (2013) Clinically occult tubal and ovarian high-grade serous carcinomas presenting in uterine samples: diagnostic pitfalls and clues to improve recognition of tumor origin. Int J Gynecol Pathol 32(5), 433-443.
    4. Fadare O, James S, Desouki MM, Khabele D (2013) Coordinate patterns of estrogen receptor, progesterone receptor, and Wilms tumor 1 expression in the histopathologic distinction of ovarian from endometrial serous adenocarcinomas. Ann Diagn Pathol 17(5), 430-433.
    5. Cathro HP, Stoler MH (2005) the utility of calretinin, inhibin, and WT-1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol 36(2), 195-201.
    6. Zhao C, Bratthauer GL, Barner R, Vang R (2007) Diagnostic utility of WT-1 immunostaining in ovarian sertoli cell tumor. Am J Surg Pathol 31(9), 1378-1386.
    7. Acs G, Pasha T, Zhang PJ (2004) WT-1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary and endometrium. Int J Gynecol Pathol 23, 110-118.
    8. Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T Kawano K, Kuwae Y, Yamauchi A, Okumura M, Kitamura Y, Oka Y, Kawase I, Sugiyama H, Aozasa K (2006) Immunohistochemical detection of WT-1 protein in a variety of cancer cells. Mod Pathol 19(6), 804-814.
    9. Chivukula M, Niemeier LA, Edwards R, Nikiforova M, Mantha G, McManus K, Carter G (2011) Carcinomas of distal fallopian tube and their association with tubal intraepithelial carcinoma: do they share a common "precursor" lesion? loss of heterozygosity and immunohistochemical analysis using PAX 2, WT-1, and P53 markers. ISRN Obstet Gynecol 2011, 858647. doi: 10.5402/2011/858647.
    10. Shimizu M, Toki T, Takagi Y, Konishi I, Fujii S (2000) Immunohistochemical detection of the Wilms tumor gene (WT-1) in epithelial ovarian tumors. Int J Gynecol Pathol 19, 158-163.
    11. Goldstein NS, Bassi D, Uzieblo A (2001) WT-1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. Am J Clin Pathol 116(2), 246-252.
    12. Al-Hussaini M, Stockman A, Foster H, McCluggage WG (2004) WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid carcinoma. Histopathol 44, 109-115.
    13. Waldstrm M, Grove A (2005) Immunohistochemical expression of Wilms' tumor gene protein in different histologic subtypes of ovarian carcinomas. Arch Pathol Lab Med 129(1), 85-88.
    14. Hsiao YH, Siddiqui S, Man YG (2010) Dual use of a single Wilms' tumor 1 immunohistochemistry in evaluation of ovarian tumors: a preliminary study of 20 cases. J Cancer 1, 93-97.
    15. Azueta A, Maiques O, Velasco A, Santacana M, Pallares J, Novell A, Llombart-Cussac A, Gonzalez-Tallada X, Mozos A, Prat J, Pillai R, Mata M, Matias-Guiu X (2013) Gene expression microarray-based assay to determine tumor site of origin in a series of metastatic tumors to the ovary and peritoneal carcinomatosis of suspected gynecologic origin. Hum Pathol 44(1), 20-28.
    16. Goldstein NS, Uzieblo (2002) WT-1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Is J Clin Pathol 117, 541-545?
    17. Hashi A, Yuminamochi T, Murata S, Iwamoto H, Honda T, Hoshi K (2003) Wilms' tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium and peritoneum. Int J Gynecol Pathol 22, 374-377.
    18. Egan JA, Ionescu MC, Eapen E, Jones JG, Marshall DS (2004) Differential expression of WT-1 and p53 in serous and endometrioid carcinomas of the endometrium. Int J Gynecol Pathol 23(2), 119-122.
    19. McCluggage WG (2006) Immunohistochemical and functional biomarkers of value in female genital tract lesions. Review. Int J Gynecol Pathol 25(2), 101-120.
    20. Soleimanpour H, Shirian S, Oryan A, Daneshbod K, Bagheri N, Daneshbod Y (2011) Cytologic, immunocytologic, histopathologic and immunohistologic diagnosis of the poorly differentiated sertoli-leydig cell tumor. Acta Cytol 55(4), 382-386.
    21. Kbel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, Ewanowich CA, Soslow RA, Gilks CB (2009) A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 33(1), 14-21?
    22. Hwang H, Quenneville L, Yaziji L, Gown AM (2004) Wilms' tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl. Immunohistochem Mol Morphol 12 (2), 122-126.
    23. Nonaka D, Chiriboga L, Soslow RA (2008) Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol 32(10), 1566-1571.
    24. Feeley KM, Wells M (2001) Precursor lesions of ovarian epithelial malignancy. Histopathol 38, 87-95.
    25. Logani S, Oliva E, Amin MB, Folpe AL, Cohen C, Young RH (2003) Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications. Am J Surg Pathol 27(11), 1434-1441.
    26. Gilks CB (2004) Subclassification of ovarian surface epithelial tumors based on correlation of histological and molecular pathologic data. Int J Gynecol Pathol 23, 200-205.
    27. Singer G, Kurman RJ, Chang HW, Cho SK, Shih IeM (2002) Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 160(4), 1223-1228.
    28. [28] Singer G, Shih IeM, Truskinovsky A, Umudum H, Kurman RJ (2003) Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int J Gynecol Pathol 22(1), 37-41.
    29. Deavers MT, Malpica A, Liu J, Broaddus R, Silva EG (2003) ovarian sex cord-stromal tumors: an immunohistochemical study including a comparison of calretinin and inhibin. Mod Pathol 16(6), 584-590.
    30. Huiying H, Daniel JL, Pei H, Sean KL, Lawrence W, Peiguo GC (2008) Expression of CD56 and WT-1 in ovarian stroma and ovarian stromal tumors. Am J Surg Pathol 32(6), 884-890.
    31. Ordonez NG (2000) Value of thyroid transcription factor-1, E-cadherin, BG8, WT-1 and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Is J Surg Pathol 24, 598-606.
    32. Han L, Pansare V, Al-Abbadi M, Husain M, Feng J (2010) Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. Diagn Cytopathol 38(5), 333-336.
    33. Lee BH, Hecht JL, Pinkus JL, Pinkus GS (2002) WT-1, estrogen receptor and progesterone receptor as marker for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Is J Clin Pathol 117, 745-750.

 

View

Download

Article ID: 2262
 
DOI: 10.14419/ijm.v2i1.2262




Copyright © 2012-2015 Science Publishing Corporation Inc. All rights reserved.